

WO9117442

Publication Title:

PROTEIN-NUCLEIC ACID PROBES AND IMMUNOASSAYS USING SAME

Abstract:

14c5 Abstract of WO9117442

In one aspect of this invention, various protein/nucleic acid hybrid probes are described which can be used to amplify the detectable signal in immunoassays. The protein moiety is capable of functioning either as an antibody or an antigen. The nucleic acid moiety serves as a signal amplifier. In another aspect, various methods of amplifying the detectable signal in immunoassays by use of the hybrid probes and related polynucleotide probes are disclosed. Data supplied from the esp@cenet database - Worldwide

Courtesy of <http://v3.espacenet.com>

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 5 : G01N 33/539, C12Q 1/68	A1	(11) International Publication Number: WO 91/17442 (43) International Publication Date: 14 November 1991 (14.11.91)
(21) International Application Number: PCT/US91/02925 (22) International Filing Date: 6 May 1991 (06.05.91) (30) Priority data: 519,212 4 May 1990 (04.05.90) US (71) Applicant: CHIRON CORPORATION [US/US]; 4560 Horton Street, Emeryville, CA 94608 (US). (72) Inventor: URDEA, Michael, S. ; 100 Bunce Meadow Road, Alamo, CA 94507 (US). (74) Agents: CIOTTI, Thomas, E. et al.; Irell & Manella, 545 Middlefield Road, Suite 200, Menlo Park, CA 94025 (US).		(81) Designated States: AT, AT (European patent), AU, BB, BE (European patent), BF (OAPI patent), BG, BJ (OAPI patent), BR, CA, CF (OAPI patent), CG (OAPI patent), CH, CH (European patent), CI (OAPI patent), CM (OAPI patent), DE, DE (European patent), DK, DK (European patent), ES, ES (European patent), FI, FR (European patent), GA (OAPI patent), GB, GB (European patent), GR (European patent), HU, IT (European patent), JP, KP, KR, LK, LU, LU (European patent), MC, MG, ML (OAPI patent), MR (OAPI patent), MW, NL, NL (European patent), NO, PL, RO, SD, SE, SE (European patent), SN (OAPI patent), SU, TD (OAPI patent), TG (OAPI patent). Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
(54) Title: PROTEIN-NUCLEIC ACID PROBES AND IMMUNOASSAYS USING SAME (57) Abstract In one aspect of this invention, various protein/nucleic acid hybrid probes are described which can be used to amplify the detectable signal in immunoassays. The protein moiety is capable of functioning either as an antibody or an antigen. The nucleic acid moiety serves as a signal amplifier. In another aspect, various methods of amplifying the detectable signal in immunoassays by use of the hybrid probes and related polynucleotide probes are disclosed.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	ES	Spain	MG	Madagascar
AU	Australia	FI	Finland	ML	Mali
BB	Barbados	FR	France	MN	Mongolia
BE	Belgium	GA	Gabon	MR	Mauritania
BF	Burkina Faso	GB	United Kingdom	MW	Malawi
BG	Bulgaria	GN	Guinea	NL	Netherlands
BJ	Benin	GR	Greece	NO	Norway
BR	Brazil	HU	Hungary	PL	Poland
CA	Canada	IT	Italy	RO	Romania
CF	Central African Republic	JP	Japan	SD	Sudan
CG	Congo	KP	Democratic People's Republic of Korea	SE	Sweden
CH	Switzerland	KR	Republic of Korea	SN	Senegal
CI	Côte d'Ivoire	LI	Liechtenstein	SU	Soviet Union
CM	Cameroon	LK	Sri Lanka	TD	Chad
CS	Czechoslovakia	LU	Luxembourg	TG	Togo
DE	Germany	MC	Monaco	US	United States of America
DK	Denmark				

5

10

PROTEIN-NUCLEIC ACID PROBES AND
IMMUNOASSAYS USING SAME

15

20

25

30

Description

Technical Field

This invention relates generally to the fields
of immunology and nucleic acid chemistry. More
specifically, it relates to the use of nucleic acid

35

-2-

hybridization as a means of amplifying the detectable signal in immunoassays.

Background Art

5 Nucleic acid hybridizations are now commonly
used in genetic research, biomedical research and
clinical diagnostics to detect and quantify particular
nucleotide sequences which are present in heterogenous
mixtures of DNA, RNA, and/or other materials. In the
10 basic nucleic acid hybridization assay, single-stranded
analyte nucleic acid (either DNA or RNA) is hybridized,
directly or indirectly, to a labeled nucleic acid probe,
and the duplexes containing label are quantified. Both
radioactive and non-radioactive labels have been used.

15 The basic assay lacks sensitivity. When the
analyte is present in low copy number or dilute
concentration the signal cannot be distinguished from the
background noise. Variations of the basic scheme have
been developed to facilitate separation of the target
20 duplexes from extraneous material and/or to amplify the
analyte sequences in order to facilitate detection, but
these variations have suffered generally from complex and
time consuming procedures, high background, low
sensitivity, and difficulty in quantification. For a
25 general discussion of these variations see International
Patent Pub. No. 89/03891.

 Immunoassays are also commonly used in genetic
research, biomedical research and clinical diagnostics to
detect and quantify particular antigenic epitopes which
30 are present in heterogenous mixtures of blood samples,
cellular extracts and other materials. A basic
immunoassay involves the specific binding of an antibody,
either monoclonal or polyclonal, to a target antigen and
a means for detecting the reaction. Such means have been
35 incorporated into various assays including direct,

-3-

indirect and sandwich immunoassays. However, the sensitivity of detection of the essential antigen/antibody interaction has presented much the same problems as described above for nucleic acid hybridizations.

Various techniques such as radioimmunoassay, immunoperoxidase, and ELISA are presently used for immunoassays. However, radioimmunoassays have the disadvantage of requiring the use of dangerous and environmentally unsound reagents and immunoperoxidase and ELISA suffer from a low signal to noise ratio and are limited in signal amplification.

A primary objective of the present invention is to provide signal amplification methods utilizing unique polynucleotide molecules, which has proved useful in nucleic acid hybridization assays, for use in immunoassays. These amplifier probes provide a highly reproducible gain in signal, a highly reproducible signal-to-noise ratio, are themselves quantifiable and reproducible, and are capable of combining specifically with an analyte antigen present at low concentration, and also with "universal" nucleic acid reporter moieties to form stable complexes.

Commonly owned US Patent No. 4,868,105, issued 19 September 1989, the disclosure of which is hereby incorporated by reference, describes a solution phase hybridization sandwich assay in which the analyte nucleic acid is hybridized to a "labeling probe" and to a "capturing probe". The probe-analyte complex is coupled by hybridization to a solid-support. This permits the analyte oligonucleotide to be removed from solution as a solid phase complex, thereby concentrating the analyte, facilitating its separation from other reagents, and enhancing its subsequent detection.

35

Commonly owned PCT application, publication no. WO90/13667, published 15 November 1990, claims linear and branched multimeric polynucleotide probes which have two domains, and methods of use of these probes as signal
5 amplifiers in nucleic acid hybridization assays. The first domain is complementary to a single-stranded oligonucleotide sequence of interest, and the second domain is comprised of a multiplicity of single-stranded oligonucleotide subunits that are complementary to a
10 single-stranded labeled oligonucleotide.

Commonly owned co-pending PCT Application, No. PCT/US91/00213, claims polynucleotide probes which have three domains, and methods of use of these probes as signal amplifiers in nucleic acid hybridization assays.
15 The first domain is complementary to a single-stranded oligonucleotide sequence of interest, the second domain is capable of functioning as a promoter for a bacterial phage DNA-dependent RNA polymerase enzyme activity, and the third domain is capable of functioning as a
20 transcriptional template for the polymerase activity.

Protein/DNA hybrid molecules have been used as probes in nucleic acid hybridization assays where the protein moiety functions as a labeling component (Czichos, J., et al, Nucl. Acids Res. (1989) 17:1563;
25 U.S. Patent No. 4,873,187; U.S. Patent No. 4,737,454.

Protein/DNA hybrid molecules have also been used as probes in immunoassays. U.S. Patent No. 4,692,509 describes a radioactively labeled hybrid probe comprising a protein and a covalently linked radioactive
30 oligonucleotide. The radioactive moiety is used to indicate the presence of the protein moiety in a biological assay. E.P.A. No. 154 884 discloses a protein/DNA hybrid molecule in which the protein moiety specifically recognizes a target protein and the nucleic
35 acid moiety provides a labeling function.

Summary of the Invention

One aspect of the invention is a polypeptide/polynucleotide-hybrid molecular probe for use
5 as an amplifier of the detectable signal in immunoassays. In one embodiment the "polymerase probe" comprises three domains:

(a) a first domain (A) which is a polypeptide and functions as an antibody specific for a known
10 antigen;

(b) a second domain (B) which is a double-stranded polydeoxyribonucleotide capable of functioning as a promoter for a DNA-dependent RNA polymerase enzyme activity; and

15 (c) a third domain (C) which is either single- or double-stranded and adjacent to the second domain, such that the third domain is capable of functioning as a template for the promoter activity of the second domain.

A second embodiment is a
20 polypeptide/polynucleotide-hybrid molecular probe for use as an amplifier of the detectable signal in immunoassays. This "multimer probe" comprises two domains:

(a) a first domain (A) which is a polypeptide capable of functioning as an antibody which binds
25 specifically to a known antigen;

(b) a second domain (M) comprising a multiplicity of single-stranded oligonucleotide subunits that are capable of binding specifically to a single-stranded nucleic acid sequence of interest; and

30 (c) a means for conjugating the first and second domains.

Another aspect of the invention is a method of amplifying a detectable signal in an immunoassay by use of the polymerase probes described supra. This method
35 comprises:

-6-

(a) immobilizing the antigenic analyte, directly or indirectly, on a solid substrate;

(b) directly or indirectly binding to the analyte a first molecular probe comprising:

- 5 (i) a binding domain (A);
 (ii) a second domain (B) which is a double stranded DNA sequence capable of functioning as a promoter for a DNA-dependent RNA polymerase enzyme activity; and

- 10 (iii) a third domain (C) which is either single- or double-stranded and adjacent to domain B, such that the third domain is capable of functioning as a template for the promoter activity of the second domain;

(c) removing the unbound probe;

- 15 (d) transcribing multiple copies of RNA oligomers which are complementary to the template sequence, c', of the third domain, C, of the probe construct via a DNA-dependent RNA polymerase activity; and

- 20 (e) quantifying the transcripts.

Another aspect of the invention is another method of amplifying a detectable signal in an immunoassay by use of the multimer probes described supra. This method comprises:

- 25 (a) immobilizing the analyte, directly or indirectly on a solid substrate;

(b) directly or indirectly binding to the analyte a hybrid molecular probe comprising:

- 30 (i) a binding domain (A) which is a polypeptide capable of functioning as an antibody which binds specifically to an antigen of interest; and

- (ii) a second domain (M) comprising a multiplicity of single-stranded DNA oligonucleotide subunits that are capable of binding specifically to a
35 single-stranded labeled oligonucleotide; and

-7-

(iii) a means for conjugating the first and second domains;

(c) removing unbound probe;

(d) hybridizing single-stranded labeled
5 oligonucleotides which comprise a nucleotide sequence which is substantially complimentary to the subunit sequence of the domain M probe to the subunits of the second domain;

(e) removing unbound labeled oligonucleotide;

10 and

(f) quantifying the amount of labeled oligonucleotide bound to the probe.

Yet another embodiment is a method of amplifying a detectable signal in a competitive
15 immunoassay which comprises:

(a) constructing a hybrid molecule in which domain A is a polypeptide capable of functioning as a hapten, and this domain is conjugated either to a B/C domain of the polymerase probe or a M domain of the
20 multimer probe;

(b) immobilizing the hybrid molecule, directly or indirectly upon a solid substrate in the presence of a competing analyte;

(c) removing the unbound probe; and either

25 (d) transcribing multiple copies of RNA oligomers via a DNA-dependent RNA polymerase activity and quantifying the transcripts - this in the instance that a polymerase probe is utilized; or

(e) hybridizing single-stranded labeled
30 oligonucleotides, to the subunits of the M domain, removing the unbound label and quantifying the bound label - this in the instance that a multimer probe is utilized.

35

Brief Description of the Drawings

Figure 1A is a schematic representation of a monomeric polymerase-type amplifier probe. Capital letters designate domains, and lower case letters designate strands within a domain. A primed letter designates a lower strand (read 3'- to 5'-, left to right). The A domain is an antibody which recognizes a target epitope. The B domain is the promoter for a RNA polymerase. The c' sequence is the template for the RNA polymerase. The probe is synthesized as a single strand. The AAAAAAA at the end of the C region represents the poly-A linker added to allow for self-annealing. The A/T region between the A and B domain is optionally required to retain full antibody activity.

Figure 1B is the DNA sequence of one embodiment of the polymerase-type amplifier probe. The promoter domain, B, consists of the consensus sequence of the bacteriophage T7 promoter (5'-TAATACGACTCACTATA-3') plus 15 additional residues 5' to the promoter sequence.

Figure 1C is a schematic representation of a multimeric polymerase-type amplifier probe in which the A domain functions as an antibody and the double stranded B and C domains are self-annealing.

Figure 1D is a schematic representation of multimeric amplifier probes in which the A domain functions as an antibody and the M domain is comprised of multiple oligomeric subunits. Both branched and comb-like multimers are depicted.

Figure 2A is a schematic representation of a sandwich immunoassay system which incorporates the polymerase-type amplifier probe. The analyte protein is indirectly immobilized upon a solid substrate by complexing with a first antibody (e.g. a "rab" (rabbit) - antibody); and indirectly joined to the amplifier probe

by complexing with a second antibody (e.g. a mouse antibody).

Figure 2B is a schematic representation of a sandwich hybridization/immunoassay system. The analyte protein is indirectly immobilized as above. The second antibody (mouse-anti-analyte) is complexed with a hybrid antibody/polynucleotide molecule in which the protein moiety functions as an anti-mouse antibody and the polynucleotide moiety is complementary to the a' nucleotide region of the amplifier probe (in this case, a multimer probe).

Figure 3 depicts the use of RNA polymerase transcripts as reporter molecules in an immunoassay. After the sandwich complex which incorporates the polymerase probe is formed, RNA polymerase is added and multiple RNA transcripts (c) complementary to the template sequence (c') are produced. These sequences have two sub-domains: c1 which is complementary to a capture probe, immobilized upon a solid substrate; and c2 which is complementary to a labelling probe. This allows for indirect immobilization of the label and easy quantification of the hybridization assay signal. "*" designates the incorporated label which may be radioactive, chemiluminescent, fluorescent or enzymatic.

Figure 4 (Parts A-F) illustrate procedures used in making multimers having "comb-like" and/or bifurcated structures.

30

35

Detailed Description of the Invention

Definitions

A "detectable signal" is a transmissible
5 indicium of the occurrence of a biochemical event such as
a nucleic acid hybridization or the binding of an antigen
and antibody. The subject application describes methods
of amplifying the detectable signal of immunoassays.

"DNA-dependent RNA polymerase" is an enzyme
10 which facilitates the polymerization of RNA of specific
sequence from a complementary DNA template.

A "domain" is a particular region of a
biochemical molecule characterized by its function.

An "epitope" is that portion of an immunogenic
15 molecule that is specifically recognized by, and
complexes with, its corresponding antibody in an
immunological reaction.

A nucleotide/peptide "hybrid" molecule comprise
both nucleic acid residues and amino acid residues, each
20 in a separate functional domain of the molecule.

An "immunogen" is a substance which can react
in a specific fashion with an antibody.

An "immunological reaction" is the specific
recognition and binding of an antibody to the epitope of
25 an immunogen. An "immunoassay" is a method of
determining the presence of an epitope by combining an
immunological reaction with a means for detecting and
quantifying the reaction.

A "polydeoxyribonucleotide" is a polymeric DNA
30 molecule. A "polynucleotide" is a polymeric DNA or RNA
molecule.

A "promoter" is the site on a
polydeoxyribonucleotide to which a RNA polymerase enzyme
binds preparatory to initiating transcription.

35

-11-

"RNA-dependent RNA polymerase" is an enzyme which facilitates the polymerization of RNA of specific sequence from a complementary RNA template.

5 "Transcription" is an process, mediated by an enzyme, by which RNA is formed from a complementary polynucleotide template.

10 The "upper strand" of a double-stranded DNA molecule is the strand whose 5'-end is on the left as the sequence is read from left to right. The sequence of this strand is always presented above the sequence for its complementary "lower strand" which is read 3'- to 5'-, left to right.

Modes for Carrying Out the Invention

15 I - Amplification Probes

A- Polymerase Probes

One aspect of this invention is a DNA amplification probe (referred to as a "polymerase probe") containing three functional domains. This probe is used
20 to enhance the detectable signal in immunoassays.

The first domain (A - Figure 1A) is a polypeptide which functions as an antibody with specificity for an antigen of choice. The functional region of the polypeptide is followed by a region of
25 either amino acid or nucleic acid residues, i.e. - a spacer region, which does not substantially interfere with the activity of the antibody. The antibody activity can be specific for an epitope of the analyte itself; however, in a preferred embodiment, the antibody is
30 directed to an antigenic determinant of the particular immunoglobulin used in the assay described infra (e.g. anti-rabbit IgG, or anti-human IgG - See Figure 2A). As applied, the analyte is contacted with a specific antibody, excess antibody is removed and the

35

-12-

amplification probe is then allowed to react with the bound antibody.

Preferably, the analyte is first immobilized upon a solid substrate to facilitate subsequent washing procedures. This immobilization may be direct (e.g. -
5 biological preparations containing the analyte might be bound to a nitrocellulose filter) or indirect (e.g. - a specific antibody might be immobilized on a solid substrate and the analyte subsequently bound to the
10 immobilized antibody).

The second domain (B - Figure 1A), usually 10 to 40 base pairs in length, preferably 20 to 35 base pairs, more preferably 30 to 35 base pairs, is double stranded and functions as a DNA-directed RNA polymerase
15 promoter. This promoter is usually derived from the promoter sequence of a bacterial phage, preferably any of the phage T3, T7, or SP6, more preferably from bacteriophage T7. This class of RNA polymerases is highly promoter specific. The T7 promoter is probably
20 the best characterized (Figure 1B). DNA sequences from 17 T7 promoters are known and a consensus sequence had been deduced: 5'-TAATACGACTCACTATA-3' (Oakley and Coleman, Proc. Nat. Acad. Sci. (1977) 74:4266; Dunn and Studier, J. Molec. Biol. (1983) 166:477). Sequences 3'
25 to the promoter on the complementary strand (the c' segment, whose 3' end is adjacent to the 5' end of the b' segment) serve as the template for transcription and the transcription of many template sequence variations can be accommodated (Figure 1B). Only the promoter region
30 itself must be double-stranded (Milligan et al, Nuc. Acids Res. (1987) 15:8783).

Extensions at the 5' end of the promoter have little effect on transcription. For example, in a preferred embodiment, the B region consists of the
35 consensus sequence of the T7 promoter plus additional

-13-

bases 5' to the consensus sequence which are identical to the sequence of the pT7 plasmids (available from US Biochemicals) up to the Pvu II restriction site (Figure 1B). These sequences may or may not be extraneous.

5 The third domain (C - Figure 1A) is directly 3' to the second domain and the c' strand of this domain serves as the template for the domain B promoter. Domain C is usually 30 to 80 nucleotides in length, preferably 35 to 50 nucleotides, most preferably 40 to 45
10 nucleotides. This domain may be either single or double stranded. The 3' end of the c' template strand (directly adjacent to the promoter) usually is a cytosine residue and consequently, the 5' end of the upper strand is usually a guanosine residue.

15 The RNA transcription product (c) of the C domain functions as a reporter molecule for the presence and quantity of analyte (Figure 3). Signal amplification occurs because each template produces 10^1 to 10^4 transcripts. The sequence of this domain is designed
20 with a random sequence, evaluated by computer analysis to minimize the possibility of cross-reaction with other probes in the system.

 The sequence of the C domain is designed for a specific detection scheme and several such schemes may be
25 employed to quantify the transcripts. For example, the transcription product (c) of the C domain may be subdivided into 2 subdomains - c_1 and c_2 (Figure 3). Subdomain c_1 is complementary to a transcript capture probe which has been immobilized on a solid substrate.
30 Subdomain c_2 is complementary to a labelling probe. After hybridization the amount of label retained is linearly proportional to the amount of analyte present in the original sample.

 In an alternate embodiment the transcript of
35 the C domain has only a c_1 subdomain. The C domain is

-14-

transcribed in the presence of labelled ribonucleotide triphosphates and the labelled transcript is subsequently bound to an immobilized transcript capture probe through its complementary c_1 subdomain and quantified.

5 In yet another embodiment the transcript of the C domain has only a c_2 subdomain. The C domain is transcribed in the presence of biotinylated ribonucleoside triphosphates and the transcripts is captured on avidin beads. The transcript is then
10 annealed to a labelling probe through its complementary c_2 subdomain and quantified.

Several other methods of labeling and detecting the transcript of the amplifying probe are possible, including the simultaneous use of labeled ribonucleotides and avidin/biotin coupling, and will be obvious to those
15 skilled in the art.

The B and C domain of polymerase probes may be prepared by cloning, enzymatic assembly, chemical cross-linking techniques, direct chemical synthesis or a
20 combination thereof. When prepared by cloning, nucleic acid sequences that encode the entire B/C domain or fragments thereof can be made in single- or double-stranded form by conventional cloning procedures.

The B domain is double stranded, and the C
25 domain may be either single or double stranded. Double stranded domains can be created in two ways: The strands can be cloned separately and subsequently the complementary strands hybridized; or alternatively, the probe can be cloned as a single stranded, self-annealing
30 polynucleotide (e.g. - b' c' c b). In this case four to ten additional nucleotides, preferably 5 - 7 nucleotides, are added to the sequence as a spacer between c and c' to allow for proper contouring of the double-stranded region when it is self-annealed. The
35 spacer is usually poly-A, but may be modified to minimize

-15-

hybridization cross-reactivity between various probes in the assay.

The A domain can be conjugated to the B/C domain through interposed linking agents such as nucleic acid, amino acid, carbohydrate or polyol bridges, or through other cross-linking agents. The B/C domain may be synthesized with a 5'-nucleic acid residue that have been derivatized to have a functional group that provides a linking site for the A domain, or the residue can be derivatized after the oligonucleotide has been synthesized to provide such a site. A preferred procedure for chemical cross-linking is to incorporate a N⁴-modified cytosine base at the 5'-end of the polynucleotide as described in the commonly owned E.P.A. Publication No. 0225807.

In a more preferred embodiment the conjugation of the B/C domain DNA to the A domain antibody can be conducted in a manner analogous to enzyme conjugation. The B/C domain is synthesized to contain an alkylamine moiety. The alkylamine is reacted with a heterobifunctional cross linking agent such as succinimidyl 4-(maleimidomethyl)cyclohexane-1-carboxylate (SMCC). After column purification, the DNA can be reacted specifically with sulfhydryl functionalities. An antibody may contain a reactive sulfhydryl (such as in reduced F(ab')₂ or may be modified to contain a sulfhydryl (such as when modified with N-succinimidyl 3-(2-pyridyldithio)propionate (SPDP) then reduced). Direct DNA-amine to antibody-amine conjugation is also possible with homobifunctional reagents, but is typically more difficult to control.

B - Multimer Probes

Another embodiment of the invention, is a DNA amplification probe (referred to as a "multimer probe") containing two functional domains, a first domain, A,

-16-

which is the same as domain A of the polymerase probe described supra, and a second (M - Figure 1D) which comprises several repeating subunits. This probe, like the polymerase probe described supra, is also used for
5 signal amplification in immunoassays.

The polynucleotide of the M domain may be a linear or branched polymer of the same repeating single-stranded oligonucleotide subunit or different single-stranded oligonucleotide subunits. These subunits
10 are capable of hybridizing specifically and stably to a single-stranded nucleotide of interest, typically a labeled oligonucleotide or another multimer. These units will normally be 15 to 50, preferably 15 to 30, nucleotides in length and have a GC content in the range
15 of 40% to 60%. The total number of oligonucleotide units in the multimer will usually be in the range of 3 to 50, more usually 10 to 20. The oligonucleotide units of the multimer may be composed of RNA, DNA, modified nucleotides or combinations thereof.

20 The oligonucleotide subunits of the multimer may be covalently linked directly to each other through phosphodiester bonds or through interposed linking agents such as nucleic acid, amino acid, carbohydrate or polyol bridges, or through other cross-linking agents that are
25 capable of cross-linking nucleic acid or modified nucleic acid strands. The site(s) of linkage may be at the ends of the subunit (in either normal 3'-5' orientation or randomly oriented) and/or at one or more internal nucleotides in the strand.

30 In linear multimers the individual subunits are linked end-to-end to form a linear polymer. In one type of branched multimer three or more oligonucleotide units emanate from a point of origin to form a branched structure. The point of origin may be another
35 oligonucleotide subunit or a multifunctional molecule to

-17-

which at least three units can be covalently bound. In another type, there is an oligonucleotide subunit backbone with one or more pendant oligonucleotide subunits. These latter-type multimers are "fork-like",
5 "comb-like" or combination "fork-" and "comb-like" in structure. The pendant units will normally depend from a modified nucleotide or other organic moiety having appropriate functional groups to which oligonucleotides may be conjugated or otherwise attached. See Figure 1D.

10 The multimer may be totally linear, totally branched, or a combination of linear and branched portions. Preferably there will be at least two branch points in the multimer, more preferably at least 15, preferably 15 to 50. The multimer may include one or
15 more segments of double-stranded sequences.


Domain M may be prepared by cloning (if linear), enzymatic assembly, chemical cross-linking techniques, direct chemical synthesis or a combination thereof. These methods of synthesis are fully disclosed
20 in the commonly owned International patent application, Pub.No. 89/03891, published 5 May 1989. In the case of linear multimers prepared by cloning, nucleic acid sequences that encode the entire multimer or fragments thereof can be made in single- or double-stranded form by
25 conventional cloning procedures. When made in double-stranded form, the multimers/fragments are ultimately denatured to provide single-stranded multimers/fragments. Multimers may be cloned in single-stranded form using conventional single-stranded
30 phage vectors such as M13. Fragments can be linked enzymatically or chemically to form the domain M multimer. When assembled enzymatically, the individual units are ligated with a ligase such as T4 DNA or RNA ligase, as the case may be. When prepared by chemical
35 cross-linking, the individual units may be synthesized

-18-

with one or more nucleic acids that have been derivatized to have functional groups that provide linking sites or derivatized after the oligonucleotide has been synthesized to provide such sites. A preferred procedure
 5 for chemical cross-linking is to incorporate N⁴-modified cytosine bases into the nucleotide as described in commonly owned E.P.A. No. 225 807, the disclosure of which is incorporated herein by reference.

When prepared by direct chemical synthesis
 10 oligonucleotides containing derivatized nucleic acids or equivalent multifunctional molecules whose functional groups are blocked are made by conventional oligonucleotide synthesis techniques. The functional groups are unblocked and oligonucleotide units are
 15 synthesized out from the unblocked site(s).

A generic structure for the molecules used to generate branch points in the multimers is as follows:




where R is an organic moiety, preferably a nucleic acid, R¹ is a hydroxyl protecting group that can be removed under conditions that do not remove synthetic nucleic
 25 acid from a solid phase and do not remove exocyclic nitrogen or phosphate protecting groups, X is a phosphorus-containing group that facilitates nucleic acid synthesis, such as a protected phosphoramidite, phosphonate or phosphate group, Y is a radical derived
 30 from a nucleophilic group such as an amino, hydroxyl, sulfhydryl or protected phosphate, and R² is R¹ or a blocking or protective group that can be removed and replaced with hydrogen without affecting R¹. In molecules used to generate bifurcated or "fork-like"
 35 branching, R¹ and R² are the same; whereas in molecules

-19-

used to generate "comb-like" branching, R_2 is a blocking group that is stable in the presence of an R^1 deblocking reagent. Figure 4 schematically illustrates the procedures used to synthesize multimers having "comb-like" branches, "fork-like" branches, or combinations thereof.


Part A of Figure 4 depicts a conventional oligonucleotide synthesis scheme for preparing a linear oligonucleotide, such as the automated phosphoramidite method (Warner et al., DNA (1984) 3:401). The dark block represents a solid support, N represents a nucleotide and p-N-OR₁ (R_1 is equivalent to R^1 below), a conventional nucleotide derivative having appropriate protecting groups.

Part B shows the procedure for making a comb-like multimer. The compound :






represents a modified base of formula (2) below. An oligomer unit of desired size and sequence is synthesized and left on the support. One or more N^4 -modified cytosine bases are then incorporated into the chain by said automated procedure. Preferably, the modified base has the formula:

-20-




where Z is a nucleophile such as -O-, -NH-, -S-, $\text{PO}_4=$, and


-OC(=O)- , R^1 is a blocking or protective group such as dimethoxytrityl (DMT) or pixyl that is generally base-stable and acid sensitive, R^2 is hydrogen or methyl, R^3 is a blocking or protective group that can be removed and replaced with hydrogen without affecting R^1 such as




-21-



5



10




R^5 is a phosphoramidite or other phosphorus derivative that enables addition of nucleotides to the 5' position of an oligonucleotide chain during chemical synthesis (e.g., a phosphodiester, phosphotriester, etc.), R^6 is methyl, hydrogen, I, Br, or F, and X is an integer in the range of 1 to 8, inclusive. When more than one modified base is incorporated they are preferably spaced by intermediate bases in the chain, most preferably by a -TT- dimer. Additional oligonucleotide units may be incorporated into the backbone followed by additional modified bases and so forth.

The N^4 nucleophile group is then deprotected (R^3 is removed) and additional oligonucleotide units are generated therefrom by the automated procedure. Residual R^1 groups at the chain termini are removed and the branched "comb-like" multimer is cleaved from the support.

Part C of Figure 4 depicts the general procedure for making "fork-like" multimers. Again, an oligomer unit of desired size and sequence is synthesized by conventional techniques and left on the support. A blocked, bifunctional phosphorus-containing group (represented as XP in Part C) such as a blocked

-22-

phosphoramidite, is then incorporated into the chain by the automated procedure. Preferred bifunctional phosphorus-containing groups are blocked phosphoramidites of the formula



where R is said hydroxyl protecting group, iPr is isopropyl, and R¹ is methyl or beta-cyanoethyl. Most
 10 preferably R is DMT and R¹ is beta-cyanoethyl.

Alternatively, the N⁴-modified cytosine base where R₁=R₂ (e.g., DMT) can be used.

The two protecting groups are then removed and additional oligonucleotide units are generated therefrom
 15 by the automated procedure. Residual R¹ groups are removed and the bifurcated multimer is cleaved from the support.

Parts D and E depict procedures where two or more bifurcated multimers, "comb-like" multimers or
 20 combinations thereof are spliced together enzymatically or chemically. Generally, the bifurcated and/or "comb-like" multimers are prepared as above and removed from the support. They are then combined in solution using the enzymatic or chemical linkage procedures
 25 described above.


Part F shows the procedure for synthesizing a multiple "comb-like" multimer. This procedure is a variation of the procedure shown in Part B and involves incorporating modified bases in the dependent side chains
 30 and generating secondary oligonucleotide side chains therefrom.

Suitable cleavable linker molecules may be incorporated into the multimers at predetermined sites for the purpose of analyzing the structure of the multimer or
 35 as a means for releasing predetermined segments (such as

-23-


the portion of the multimer that binds to the labeled oligonucleotide). Subsequent to multimer synthesis and purification these linkers can be cleaved specifically without additional degradation of the nucleotide

5 structure of the multimer. A preferred type of linker molecule was designed to contain a 1,2-diol group (which can be cleaved selectively by periodates) as well as a protected hydroxyl and phosphoramidite derived hydroxyl group to permit the linker to be incorporated into any
10 DNA fragment by standard phosphoramidite chemistry protocols. A preferred embodiment of such a linker is the compound:




where DMT and iPr are as defined previously. After incorporation into a DNA fragment and complete deprotection the linker-containing fragment has the following structure:

25



where DNA₁ and DNA₂ represent DNA subfragments which may be the same or different. Reaction of this fragment with sodium periodate cleaves the fragment into the following
35 subfragments:

-24-



Alternatively, the 1,2-diol group may be replaced with linker groups that contain a hydroxylamine-sensitive linkage, a base-sensitive sulfone linkage, or a thiol-sensitive disulfide linkage. Such linker groups may be derived from conventional cross-linking agents that are used to conjugate proteins to other entities. Likewise, protecting groups other than DMT may be used.

The functional aspects of the polymerase probe may be combined with the multimer probe structure by synthesizing a multimer probe having a M domain with subunits comprising multiples of the promoter/template (B/C) domains of the polymerase probe. Like multimer probes the multimeric subunits may be either in a linear array or branched molecules.

Like polymerase probes, the A domain of multimer probes can be conjugated to the M domain through interposed linking agents such as nucleic acid, amino acid, carbohydrate or polyol bridges, or through other cross-linking agents. The M domain may be synthesized with a 5'-nucleic acid residue that has been derivatized to have a functional group that provides a linking site for the A domain, or the residue can be derivatized after the oligonucleotide has been synthesized to provide such a site. A preferred procedure for chemical cross-linking is to incorporate a N⁴-modified cytosine base at the 5'-end of the polynucleotide as described in the commonly

35

-25-

owned E.P.A. publication No. 0225807 and in Section I(A),
supra.

II - Immunoassays

5 Another aspect of this invention employs
amplifier probes in immunoassays to detect and quantify
the presence and concentration of an immunologic analyte.
These amplifier probes are of two classes: the hybrid
probes disclosed in Sec. I supra (either polymerase
10 probes or multimer probes); or the polynucleotide probes
disclosed in U.S. Serial No. 463,022 and U.S. Serial No.
340,031. These probes are similar to the hybrid probes,
but with A domains comprised of a polynucleotide sequence
rather than a polypeptide.

15 The analyte may be any known immunogen of
interest. The analyte may be present in low concentration
in a prepared sample or it may be a minority species in a
heterogeneous mixture of biological material. The
analyte may be present in a variety of sources, e.g.,
20 biological fluids or tissues, food stuffs, environmental
materials, etc., or it may be synthesized in vitro.

In a first step, the sample containing the
analyte is prepared by any of a variety of methods known
to those skilled in the art.

25 Amplifier probes can be employed to detect an
analyte in any number of immunoassay protocols -
conducted either in solution or immobilized upon a solid
phase. If the immunoassay is conducted in solution, the
sample containing the analyte is either bound to the
30 amplifier probe directly; indirectly through one or more
antibodies specific for the analyte; or, if a
polynucleotide probe is employed, in conjunction with a
hybrid linker molecule (discussed in Sec II(B), infra).
Amplifier probes can be utilized in this fashion in most

35

-26-

soluble immunoassay protocols. See, for example, U.S. Patent No. 4,778,751.

In an immunoassay utilizing a solid phase, the analyte (which can either be an antigen or an antibody) is either immobilized directly upon a solid phase; indirectly by binding the analyte to a first antibody that has first been bound to a solid phase; or by a sandwich assay (Figure 2A) in which a second antibody recognizes the analyte and in turn is recognized by the first antibody bound to the solid phase.

If the analyte is to be directly bound to a solid phase, the sample containing analyte is contacted with a nitrocellulose filter or similar means for non-selectively binding protein. If the analyte is to be indirectly and selectively bound to a solid phase a first antibody, directed to an epitope of the analyte or to a second antibody, is conjugated to the solid phase and subsequently used to bind the analyte or a second antibody bound to the analyte.

20

A - Using Hybrid Probes

An additional antibody, directed to a second epitope of the analyte can then be employed as a linker between the analyte and an amplifier probe. The amplifier probe, either a polymerase probe or a multimer probe, whose A domain is directed to the second antibody, can then be conjugated to the linker antibody, forming a string consisting of the first antibody bound to a solid phase, a second antibody, the analyte, a linker antibody, and the amplifier probe (Figure 2A).

30

B - Using Polynucleotide Probes

In an alternate embodiment, the amplifier probe employed is one of the polynucleotide multimer probes disclosed in International Publication No. 89/03891.

35

-27-

These probes differ from the peptide/nucleotide-hybrid multimer probes of the instant application in that domain A is a polynucleotide sequence rather than an antibody-functioning polypeptide. Consequently, an

5 antibody/polynucleotide hybrid linker must be employed to indirectly couple the analyte to the amplifier probe (Figure 2B). This hybrid linker has a first domain, which is a polypeptide that functions as an antibody specific for an epitope of the analyte or an epitope of

10 an antibody which recognizes the analyte; and a second domain which is a nucleotide sequence substantially complementary to the nucleotide sequence of the A domain of the amplifier probe.

Similarly, in an alternate embodiment, one of

15 the polynucleotide polymerase probes disclosed in U.S. Application No. 463,022 may be employed. These probes differ from the hybrid polymerase probes of the instant application in that domain A is a polynucleotide sequence rather than an antibody functioning polypeptide. These

20 probes also require the use of a hybrid linker as described supra.

By using a polynucleotide amplifier probe and a hybrid linker rather than the hybrid amplifier probes described in Section I, supra, the amplifier probe can be

25 a "universal" reagent, useful for both nucleic acid hybridization assays and immunoassays.

C - Binding and Hybridization Conditions

In a preferred embodiment, the analyte is indirectly immobilized upon a solid phase, for example a

30 96-well polyvinyl chloride (PVC) plate. In the sandwich assay depicted in Figure 2A, 50 μ l of the first antibody (anti-rabbit at a concentration of 20 μ g/ml in 0.2M NaHCO₃) is added to a well. The well is covered and incubated for 2 hours at room temperature in a humidified

35 atmosphere. The solution is then aspirated from the

-28-

well. The well is then washed twice with a blocking buffer comprising 3% bovine serum albumin in phosphate buffered saline solution containing 0.02% sodium azide. The well is next incubated with blocking buffer for 20
5 minutes at room temperature in a humidified atmosphere and then washed twice more with blocking buffer.

50 μ l of the second antibody (rabbit-anti analyte also at a concentration of 20 μ g/ml) is added to the well and the procedure described above is repeated.
10 Next series of dilutions, in blocking buffer, of the analyte is prepared. 50 μ l of each dilution is added to a well. The plate is covered and incubated for 2 hours at room temperature in a humidified atmosphere. Following this incubation the wells are washed four times with
15 blocking buffer. The third antibody (mouse-anti-analyte) is next added in the same fashion, followed by addition of the hybrid amplifier probe. Since occasional tissue preparations may contain anti-DNA antibodies, the blocking buffer used for the washes which follow the
20 addition of the probe also contains 20 μ g/ml salmon sperm DNA.

When polynucleotide amplifier probes or hybrid multimer probes are used, a nucleic acid hybridization step follows the complexing of the analyte and
25 antibodies. Usually, hybridization conditions consist of an aqueous medium, particularly a buffered aqueous medium, which includes various additives. These additives can include the polynucleotides to be hybridized, salts (e.g. sodium citrate 0.017M to 0.17M and/or sodium
30 chloride 0.17M to 1.7M), non-ionic detergents such as NP-40 or Triton X-100 (0.1 to 1.0%) which do not interfere with the antigen/antibody complex, and carrier nucleic acids. The mixture is incubated for 15 to 75 minutes at 35°C to 55°C.

35

-29-

If the conditions employed for hybridization of the labeled oligonucleotide to the multimer subunits causes instability in the antigen/antibody complexes, the hybridization step can be preceded by treatment of the complex with a protein crosslinker such as glutaraldehyde, or a similar method of stabilizing the complex. Once the protein complex is stabilized, conditions of nucleic acid hybridization may be altered to include SDS (up to 1%); nonaqueous solvents such as dimethylformamide, dimethylsulfoxide, and formamide; and temperatures up to 70°C.

It is important to adjust nucleic acid hybridization conditions to maintain the stability of the antigen/antibody complexes. For example, the hybridization of shorter stretches of complementary sequences can be accomplished at lower temperatures. In a preferred embodiment, complementary single-stranded regions are 12 to 20 bases. In a preferred embodiment, the hybridization temperature is 35 to 45 degrees C. Furthermore, since the only single-stranded oligonucleotides present at this step are the complementary strands, higher stringency and consequently lower salt concentrations (0.3M Na) can be tolerated.

1 - Multimer Probe

If a multimer probe is employed, labeled oligonucleotide which is substantially complementary to the repeating polynucleotide of the M domain is subsequently added under conditions which permit it to hybridize to the complementary oligonucleotide units of the multimer. The resulting solid phase labeled nucleic acid complex is then separated from excess labeled oligonucleotide, by washing to remove unbound labeled oligonucleotide, and read.

-30-

The amplification may be multiplied by the use of more than one species of multimer (as defined by subunit sequence) in the assay. In such instances a second multimer is designed to bind to the repeat sequence of the first multimer and the complex is subsequently labeled with an oligonucleotide that is substantially complementary to the repeat sequence of the second multimer. Any number of multimers may be bound in series in this manner to achieve even greater amplification.

2 - Polymerase Probe

If a polymerase probe is employed, the RNA polymerase specific for the promoter region (domain B) of the amplifier probe is next added under appropriate transcription conditions and multiple RNA copies (c) of the C domain template (c') are produced. The amount of transcript is proportional to the quantity of the analyte in the initial preparation.

Transcription conditions consist of an aqueous medium, preferably a buffered aqueous medium, with appropriate salts, usually including a magnesium salt, rATP, rUTP, rGTP, rCTP, a RNA polymerase enzyme and usually include various denaturing agents, protein carriers, and RNase inhibitors. Incubation is usually for 15 to 90 minutes, usually 60 minutes; and at a temperature which is optimal for the chosen enzyme, usually 35°C to 42°C, usually 37°C.

The sequence of the C domain is designed for a specific detection scheme and several such schemes may be employed to quantify the transcripts. For example, the transcription product (c) of the C domain may be subdivided into 2 subdomains - c_1 and c_2 (Figure 2B). Subdomain c_1 is complementary to a transcript capture probe which has been immobilized on a solid substrate. Subdomain c_2 is complementary to a labelling probe.

After hybridization the amount of label retained is linearly proportional to the amount of analyte present in the original sample.

5 In an alternate embodiment the transcript of the C domain has only a c_1 subdomain. The C domain is transcribed in the presence of labelled ribonucleotide triphosphates and the labelled transcript is subsequently bound to an immobilized transcript capture probe through its complementary c_1 subdomain and quantified.

10 In yet another embodiment the transcript of the C domain has only a c_2 subdomain. The C domain is transcribed in the presence of biotinylated ribonucleoside triphosphates and the transcripts is captured on avidin beads. The transcript is then
15 annealed to a labelling probe through its complementary c_2 subdomain and quantified.

Several other methods of labeling and detecting the transcript of the amplifying probe are possible, including the simultaneous use of labeled ribonucleotides and avidin/biotin coupling, and will be obvious to those
20 skilled in the art.

3 - General Considerations

The solid phase that is used in the assay may be particulate or be the solid wall surface of any of a
25 variety of containers, e.g., centrifugal tubes, columns, microtiter plate wells, filters, tubing, etc. Preferably, particles will be employed of a size in the range of about 0.4 to 200 microns, more usually from about 0.8 to 4.0 microns. The particles may be any
30 convenient material, such as latex, or glass. The first antibody specific for the analyte, or for a second antibody which is specific for the analyte, may be stably attached to the solid surface through functional groups by known procedures.

The labeling probes will, if polymerase probes are employed, include sequences complementary to the c₂ subdomain of the transcripts of the amplifier probe; and if multimer probes are employed, labeling probes will include sequences complementary to the repeating units of the B domain. The labelling probe will include one or more molecules ("labels"), which directly or indirectly provide for a detectable signal. The labels may be bound to individual members of the complementary sequence or may be present as a terminal member or terminal tail having a plurality of labels. Various means for providing labels bound to the sequence have been reported in the literature. See, for example, Urdea *et al.*, Nucl. Acids Res. (1988) 16:4937, Leary *et al.*, Proc. Natl. Acad. Sci. USA (1983) 80:4045; Renz and Kurz, Nucl. Acids Res. (1984) 12:3435; Richardson and Gumpert, Nucl. Acids Res. (1983) 11:6167; Smith *et al.*, Nucl. Acids Res. (1985) 13:2399; Meinkoth and Wahl, Anal. Biochem. (1984) 138:267. The labels may be bound either covalently or non-covalently to the complementary sequence. Labels which may be employed include radionuclides, fluorescers, chemilumescers, dyes, enzymes, enzyme substrates, enzyme cofactors, enzyme inhibitors, enzyme subunits, metal ions, and the like. Illustrative specific labels include fluorescein, rhodamine, Texas red, phycoerythrin, umbelliferone, luminol, NADPH, galactosidase, horseradish peroxidase, etc. See Urdea *et al.* for a comparison of non-radioisotopic labelling methods.

The labelling probes can be conveniently prepared by chemical synthesis such as that described in commonly owned E.P.A. Pub. No. 225807. By providing for a terminal group which has a convenient functionality, various labels may be joined through the functionality. Thus, one can provide for a carboxy, thiol, amine, hydrazine or other functionality to which the various

-33-

labels may be joined without detrimentally affecting duplex formation with the sequence. As already indicated, one can have a molecule with a plurality of labels joined to the sequence complementary to the labeling sequence. Alternatively, one may have a ligand bound to the labeling sequence and use a labeled receptor for binding to the ligand to provide the labeled analyte complex.

Depending upon the nature of the label, various techniques can be employed for detecting the presence of the label. For fluorescers, a large number of different fluorometers are available. With enzymes, either a fluorescent or a colored product can be provided and determined fluorometrically, spectrophotometrically or visually. The various labels which have been employed in immunoassays and the techniques applicable to immunoassays can be employed with the subject assays.

The procedure used in the separation steps of the assay will vary depending upon the nature of the solid phase. For particles, centrifugation or filtration will provide for separation of the particles, discarding the supernatant or isolating the supernatant. Where the particles are assayed, the particles will be washed thoroughly, usually from one to five times, with an appropriate buffered medium containing detergent, e.g., PBS with SDS. When the separation means is a wall or support, the supernatant may be isolated or discarded and the wall washed in the same manner as indicated for the particles.

30

D. Competitive Immunoassays

The hybrid amplifier probes of the subject invention can also be employed as a means for labeling antigen in a competitive immunoassay. In the typical assay, excess antibody, polyclonal or monoclonal,

35

preferably monoclonal, which specifically binds to the analyte, is immobilized upon a solid phase, usually in a multiple well plate. A standard concentration of labeled antigen is mixed with serial dilutions of a sample
5 thought to contain an unknown amount of analyte. The separate dilutions are then exposed to the immobilized antibody and the amount of bound label is measured. The ability of the unlabeled analyte to compete with the labeled analyte is used to calculate the amount of
10 analyte in the sample.

In one embodiment, a B/C domain polynucleotide moiety of the polymerase probe is conjugated to a competitive immunogen. This hybrid molecule is then used as the labeled antigen described supra. After the
15 competitive binding, polymerase (specific for the B domain promoter) is added and the transcription product is assayed as described in Section I(A), supra.

In another embodiment, a M domain polynucleotide moiety of the multimer probe is conjugated
20 to a competitive immunogen. This hybrid molecule is then used as the labeled antigen described supra. After the competitive binding, the M domain is labeled and quantified as described, supra.

For immunogen coupling to DNA, homobifunctional
25 reagents such as disuccinimidyl suberate (DSS), ethylene glycol bis(succinimidylsuccinate) (EGS), or p-phenylene diisothiocyanate (DITC), are probably more useful coupling methods than those described in Section I(A), supra.

30 Kits for carrying out amplified immunoassays according to the invention will comprise, in packaged combination, the following reagents: a solid phase that is either capable of binding the antigen analyte or alternatively already has a linking first antibody bound
35 to it if the assay format is one in which the analyte is

indirectly bound to the solid phase through a bound first antibody or through a second antibody; optionally linker second and third antibodies which are specific for the analyte, and a hybrid linker probe if the assay format is one in which a polynucleotide amplifier probe is used; the amplifier probe; the appropriate DNA-directed RNA polymerase and immobilized transcription capture probes (if a polymerase amplifier probe is used); and an appropriate labelling probe; These reagents will typically be in separate containers in the kit. The kit may also include hybridization buffers, wash solutions, negative and positive controls and written instructions for carrying out the assay.

The following examples are presented as illustrations, not limitations, of the present invention. Other embodiments within the spirit and scope of the invention will suggest themselves to those skilled in the art.

Example 1 - Immunoassay for the Presence of an HCV Antigen in Human Serum

This assay is designed to test directly for the presence of the C-100 antigen of the Hepatitis C virus. The general protocol for this immunoassay is as described, supra. Microtiter plates are prepared using goat-anti-mouse as the first antibody. This antibody is immobilized in the wells of a 96-well microtiter plate. The second antibody is a mouse monoclonal antibody specific for an epitope of HCV C-100. Duplicate dilutions of serum from individuals to be screened for HCV are prepared in blocking buffer and incubated in the microtiter wells along with appropriate non-infected controls. The third antibody is a combination of polyclonal rabbit-antibodies which recognizes each of the HCV antigens. The final antibody is a hybrid T7

-36-

polymerase amplifier probe. The domain A polypeptide moiety functions as a goat-anti-rabbit antibody and completes the immunoassay "sandwich".

After addition of the T7 polymerase probe,
5 transcription of domain C is effected by incubating the complex in 20 μ l of a solution containing 40 mM Tris HCl (pH 8), 20 mM $MgCl_2$, 10 mM NaCl, 1mM Spermidine, 10 mM Dithiothreitol, 0.15 mg/ml Bovine Serum Albumin, 1.25 mM each of rATP, rCTP, rGTP, rUTP, 1600 units/ml RNasin, and
10 2000 units/ml T7 RNA polymerase. This mixture is incubated at 37 $^{\circ}$ C for 1 hour. Transcription is terminated by addition of 20 μ l of a solution containing 8 X SSC, and 0.2% SDS and the entire mixture is transferred to new wells containing an immobilized
15 capture probe with c_1' sequences. Capture of the domain C transcripts (Figure 3) is effected by incubation at 55 $^{\circ}$ C for 1 hour followed by two washes with 0.1 X SSC, 0.1% SDS.

The domain C transcripts are then labelled by
20 addition of 50 fmol of enzyme-labeled probe (c_2') in 40 μ l of 4 X SSC, 100 μ g/ml poly A for 15 min. at 55 $^{\circ}$ C. Finally, the complex was washed twice with 0.1 X SSC, 0.1% SDS, followed by two washes with 0.1X SSC.

For AP detection, an enzyme-triggered dioxetane
25 reaction (Schapp et al. (1987) Tet. Lett. 28: 1159-1162 and US Patent 4,857,652), obtained from Lumigen Inc., is employed. The detection procedure is as follows. For the labeling step 20 μ l HM buffer with the AP probe is added to each well and the wells are incubated at 55 $^{\circ}$ C
30 for 15 min. The supernatant is removed and the wells are washed 2 x with 380 μ l of 0.1 x SSC and 0.1% SDS. The wells are then washed 2 x with 380 μ l of 0.1 x SSC to remove any remaining SDS. 20 μ l of 3.3×10^{-4} M dioxetane in CTAB buffer is added to each well. The
35 wells are tapped lightly so that the reagent falls to the

-37-

bottom and gently swirled to distribute the reagent evenly over the bottom. The wells are covered with the microtiter plate sealer and incubated in a 37°C oven for one hour. The wells are then read with a luminometer, and quantified relative to a standard curve generated with known amounts of antigen.

Example 2 - Immunoassay for the Presence of Antibody to HCV in Human Serum

Microtiter plates are first coated with the HCV C-100 antigen from the Hepatitis C virus. A solution containing coating buffer (50mM Na Borate, pH 9.0), 21 ml/plate, BSA (25µg/ml), HCV C-100 (2.50µg/ml) is prepared just prior to addition. After mixing for 5 minutes, 0.2ml/well of the solution is added to the plates, they are covered and incubated for 2 hours at 37°C, after which the solution is removed by aspiration. The wells are washed once with 0.4ml wash buffer (100mM Na phosphate, pH 7.4, 140mM NaCl, 0.1% casein, 1% (w/v) Triton X-100, 0.01% (w/v) Hixitane). After removal of the wash solution, 200 µl/well of Postcoat solution (10mM Na phosphate, pH7.2, 150mM NaCl, 0.1% (w/v) casein, 3% sucrose and 2mM phenylmethylsulfonylfluoride (PMSF), is added, the plates are loosely covered to prevent evaporation, and are allowed to stand at room temperature for 30 minutes. The wells are then aspirated to remove solution, and lyophilized dry overnight, without shelf heating.

To perform the immunoassay, 20µl of duplicate dilutions of serum samples or controls are added to wells containing 200µl of sample diluent (100 mM Na phosphate, pH 7.4, 500mM NaCl, 1mM EDTA, 0.1% (w/v) casein, 0.01% (w/v) Hixitane, 1% (w/v) Triton X-100, 100µg/ml yeast extract). The plates are sealed, and incubated at 37°C for 2 hours, after which the solution is removed by

-38-

aspiration, and the wells are washed 3 times with 400 μ l of wash buffer (PBS containing 0.05% Tween 20).

Subsequent to the addition of serum samples, the wells are treated as in Example 1, above, except that
5 rabbit-anti-human serum is substituted for the third antibody (rabbit-anti-analyte).

Example 3 - Use of Multimer Probes in the Detection of HCV Infection

10 In either of the two examples above, multimer probes can be substituted for polymerase probes. All steps are the same in each example up through the addition of amplifier probe, except of course that a multimer probe is used rather than a polymerase probe.
15 Subsequent to the binding of the amplifier probe, a solution of with 50fmol of a labeled oligonucleotide sequence with substantial homology to the multimeric subunit of the M domain is added. This enzyme-labeled probe is added in 40 μ l of 4 X SSC, 100 μ g/ml poly A for
20 15 min. at 55°C. Finally, the complex was washed twice with 0.1 X SSC, 0.1% SDS, followed by two washes with 0.1X SSC.

For AP detection, an enzyme-triggered dioxetane reaction (Schapp et al. (1987) Tet. Lett. 28: 1159-1162
25 and US Patent 4,857,652), obtained from Lumigen Inc., is employed. The detection procedure is as follows. For the labeling step 20 μ l HM buffer with the AP probe is added to each well and the wells are incubated at 55°C for 15 min. The supernatant is removed and the wells are
30 washed 2 x with 380 μ l of 0.1 x SSC and 0.1% SDS. The wells are then washed 2 x with 380 μ l of 0.1 x SSC to remove any remaining SDS. 20 μ l of 3.3×10^{-4} M dioxetane in CTAB buffer is added to each well. The wells are tapped lightly so that the reagent falls to the
35 bottom and gently swirled to distribute the reagent

-39-

evenly over the bottom. The wells are covered with the microtiter plate sealer and incubated in a 37°C oven for one hour. The wells are then read with a luminometer, and quantified relative to a standard curve generated with known amounts of antigen.

Example 4 - Use of Polynucleotide Polymerase Probes in the Detection of HCV Infection

In either of Examples 1 or 2 above,

10 polynucleotide polymerase probes can be substituted for the hybrid polymerase probes. All steps are the same in each example up through the addition of the third antibody which is a combination of polyclonal rabbit-antibodies which recognizes each of the HCV antigens.

15 This is followed by addition of 50µl of a hybrid linker molecule at a concentration of 20µg/ml in 0.2M NaHCO₃. This incubation is conducted according to the same protocol as all previous antibody incubations. The hybrid linker molecule has a first domain which functions

20 as an anti-rabbit antibody and binds to the all previously bound rabbit third-antibodies. The second domain of the hybrid linker is an oligonucleotide with 15 residues the sequence of which is substantially complementary to domain A of the polynucleotide

25 polymerase probe. After incubation and washing the polymerase probe is added in 50µl of hybridization buffer (0.3M NaCl, 0.1% NP-40) and incubate for 60 minutes at 40°C. After incubation excess probe is removed and the complex is washed 3 times with hybridization buffer.

30 Domain B is transcribed and the transcription quantified as described in Example 1.

Example 5 - Use of Polynucleotide Multimer Probes in the Detection of HCV Infection.

This assay is identical to that described in Example 4, up through the addition of the polynucleotide probe. Subsequent hybridization of label to the domain M subunits and quantification of label is the same as in Example 3.

Example 6 - Use of Polynucleotide Multimer Probe in the Detection of Immobilized Human IgG

A comb-like branched polynucleotide having 15 dependent side chains each containing three sites (total of 45 sites) complementary to a labeled probe and a terminal biotin molecule attached to the backbone was prepared as described above.

Human IgG at various concentrations was immobilized on a solid support. The immobilized IgG was incubated with biotinylated affinity purified goat anti-human IgG (biotin concentration 40 ng) and excess antiserum was washed from the support. The support was then incubated with 200 ng avidin-D and then with 100 fm or 500 fm of the comb-like branched polynucleotide, with appropriate washings. The support was then incubated with horseradish peroxidase labeled oligonucleotide probe complementary to the labeled probe binding sites on the polynucleotide. Optical density (O.D.) readings were made at 492/620 nm.

For comparison purposes, assays were run as above using a polynucleotide with only one labeled probe binding site.

The table below presents the results of these tests.

-41-

O.D.

	<u>Human IgG Conc.</u> <u>(ng/ml)</u>	<u>45 site</u> <u>@ 100 fm</u>	<u>1 site</u> <u>@ 100 fm</u>	<u>45 site</u> <u>@ 500 fm</u>	<u>1 site</u> <u>@ 500 fm</u>
5	100	1.116	0.005	2.505	0.002
	50	1.089	0.002	1.564	0.001
	25	0.432	0.001	1.295	0.001
	12.5	0.303	0.001	0.451	0

10 As reported, the 45 site polynucleotide
provided a much higher signal than the single site
polynucleotide.

15 Other variations and applications of the
various amplifier probes described in this application to
methods of immunoassay will be obvious to those skilled
in the art and are intended to be within the scope of the
subject invention.

20

25

30

35

-42-

CLAIMS

1. A molecular probe for use as a signal amplifier in immunoassays comprising:
 - 5 (a) a first domain (A) which is a polypeptide and functions as an antibody specific for a known antigen;
 - (b) a second domain (B) which is a double-stranded polynucleotide capable of functioning as a promoter for a DNA-dependent RNA polymerase enzyme activity; and
 - 10 (c) a third domain (C) which is either single- or double-stranded and adjacent to the second domain, such that the third domain is capable of functioning as a template for the promoter activity of the second domain.
2. The probe of claim 1 in which the DNA-dependent RNA polymerase activity is derived from the bacteriophage T7.
- 20 3. The probe of claim 1 or 2 in which the second domain B is at least 10 and no more than 40 nucleotides long.
4. The probe of claim 3 in which the third domain C is at least 30 and no more than 80 nucleotides long.
- 25 5. The probe of claim 2 wherein the polymerase activity is derived from the bacteriophage T7 and the sequence for the second domain B comprises the sequence:
 - 30 5'-TAA TAC GAC TCA CTA TA-3'
 - 3'-ATT ATG CTG AGT GAT AT-5'
6. The probe of claim 2 wherein the polymerase activity is derived from the bacteriophage T7 in which the nucleotide sequence of the second domain B is:
35

5'-CTG GCT TAT CGA AAT TAA TAC GAC TCA CTA TA-3'
3'-GAC CGA ATA GCT TTA ATT ATG CTG AGT GAT AT-5'

- 5 7. The probe of claim 1, 2, 3, 4, 5 or 6 in which the 5' residue of the upper strand of the nucleotide sequence for the third domain C, is adjacent to the second domain B, and is a guanosine residue.
- 10 8. The probe of claim 1, 2, 3, 4, 5, 6 or 7 in which the sequence for the third domain C is:
- 5'-GGG AGA TGT GGT TGT CGT ACT TAG CGA AAT ACT GTC CGA
GTC G-3'
- 15 3'-CCC TCT ACA CCA ACA GCA TGA ATC GCT TTA TGA CAG GCT
CAG C-5'
- 20 9. The probe of claim 8 in which the 3' end of the upper strand of the DNA nucleotide sequence of the second domain B is attached to the 5' end of the upper strand of the nucleotide sequence of domain C.
- 25 10. The probe of claim 1 in which the transcript of the third domain C has two subdomains:
- (a) a first subdomain, c_1 , which is capable of hybridizing to an oligonucleotide capture linker, the capture linker being capable of hybridizing to a polynucleotide immobilized on a solid substrate; and
- 30 (b) a second subdomain, c_2 , which is capable of binding to an oligonucleotide label linker, the label linker capable of binding to a quantifiable probe.
- 35 11. The probe of claim 1 in which a functional unit comprising the second and third domains, B and C, are present in multiple repeating units.

12. A method of amplifying a detectable signal in an immunoassay which comprises:

- 5 (a) directly or indirectly binding to an analyte a biochemical molecular probe comprising a binding domain (A), a second domain (B) which is a double stranded DNA sequence capable of functioning as a promoter for a DNA-dependent RNA polymerase enzyme activity, and a third domain (C) which is either single-
10 or double- stranded and adjacent to domain B, such that the third domain is capable of functioning as a template for the promoter activity of the second domain;
- (b) removing unbound probe;
- (c) transcribing multiple copies of RNA
15 oligomers which are complementary to the template sequence, c', of the third domain, C, of the probe construct via a DNA-dependent RNA polymerase activity; and
- (d) quantifying the RNA transcripts.
20

13. The method of claim 12 in which the analyte is first immobilized, directly or indirectly, upon a solid substrate.

- 25 14. The method of claim 12 or 13 in which domain A is a polypeptide capable of functioning as an antibody, and the probe is bound directly or indirectly to the analyte through domain A.

- 30 15. The method of claim 12 or 13 in which:

(a) domain A of the probe is a single-stranded polynucleotide; and

- (b) the analyte is indirectly bound to the molecular probe via a protein/polynucleotide hybrid
35 linker molecule with two domains:

-45-

(i) a first domain which is a single-stranded polynucleotide sequence substantially complementary to the sequence of domain A of the probe; and

5 (ii) a second domain which functions as an antibody, specific for the analyte, or for an epitope of an antibody which is specific for the analyte.

16. The method of claim 12, 13, 14 or 15 in which the
10 second domain, B, is derived from the DNA-dependent RNA polymerase of the bacteriophage T7.

17. The method of claim 12, 13, 14, 15 or 16 in which:

(a) the third domain, C, of the probe is
15 transcribed in the presence of labeled ribonucleotide triphosphates;

(b) the transcripts of the third domain have a first subdomain, c_1 , complementary to an oligonucleotide capture probe which is immobilized on a solid substrate;
20 and

(c) said transcripts are immobilized and quantified.

18. The method of claim 12, 13, 14, 15 or 16 in which:

25 (a) the third domain, C, of the first probe is transcribed in the presence of biotinylated ribonucleotides triphosphates;

(b) the transcript of the third domain has a first subdomain, c_2 , which is complementary to a labeled
30 oligonucleotide probe;

(c) the transcripts are immobilized upon an avidinylated solid substrate; and

(d) the transcripts are quantified.

35

-46-

19. The method of claim 12, 13, 14, 15 or 16 in which:
- (a) the third domain, C, of the probe is transcribed in the presence of both labeled and biotinylated ribonucleotide triphosphates;
 - 5 (b) the transcripts are immobilized upon an avidinylated solid substrate; and
 - (c) the transcripts are quantified.
20. The method of claim 12, 13, 14, 15 or 16 in which:
- 10 (a) the transcript of the third domain, C, of the probe has two subdomains:
 - (i) a first subdomain, c1, which is complementary to an oligonucleotide capture probe, the capture probe being immobilized on a
 - 15 solid substrate; and
 - (ii) a second subdomain, c2, which is complementary to a labeled oligonucleotide probe;
 - (b) the transcript is hybridized to the capture
 - 20 probe;
 - (c) the labeled probe is hybridized to said transcript; and
 - (d) the labeled probe is quantified.
- 25 21. The method of claim 12 in which a unit comprising the second and third domains, B and C, of the first probe are present in multiple repeating B/C units.
- 30 22. A molecular probe for use as a signal amplifier in immunoassays comprising:
- (a) a first domain (A) comprising a polypeptide capable of functioning as an antibody which binds specifically to a known analyte; and
 - (b) a second domain (M) comprising a
 - 35 multiplicity of single-stranded oligonucleotide subunits

-47-


that are capable of binding specifically to a single-stranded nucleic acid sequence of interest.

23. The probe of claim 22 in which each oligonucleotide unit of the second domain, M, comprises about 15 to 50 bases and has a GC content in the range of about 40% to about 60%.

24. The probe of claim 22 in which the molecule has a linear structure.

25. The probe of claim 22 in which the molecule has a branched structure.

26. The probe of claim 22 wherein at least a portion of the oligonucleotide subunits of the second domain are linked via a multifunctional moiety derived from a compound of the formula:



where R is an organic moiety, preferably a nucleic acid, R^1 is a hydroxyl protecting group that can be removed under conditions that do not remove synthetic nucleic acid from a solid phase and do not remove exocyclic nitrogen or phosphate protecting groups, X is a phosphorus-containing group that facilitates nucleic acid synthesis, Y is a radical derived from a nucleophilic group, and R^2 is R^1 or a blocking or protective group that can be removed and replaced with hydrogen without affecting R^1 .

35


-48-

27. The probe of claim 22 wherein at least a portion of the oligonucleotide subunits are linked via a multifunctional moiety derived from a compound of the formula:

5

10

15



(2)


20 where Z is a nucleophile, R^1 is a protective group that is generally base-stable and acid sensitive, R^2 is hydrogen or methyl, R^3 is a protective group that can be removed and replaced with hydrogen without affecting R^1 , R^5 is a phosphorus derivative that enables addition of
 25 nucleotides to the 5' position of an oligonucleotide chain during chemical synthesis, R^6 is methyl, hydrogen, I, Br, or F, and X is an integer in the range of 1 to 8, inclusive.

30

28. The probe of claim 22 wherein at least a portion of the oligonucleotide subunits are linked via a multifunctional moiety derived from a compound of the formula:

35

-49-



5 where R is said hydroxyl protecting group, iPr is isopropyl, and R¹ is methyl or beta-cyanoethyl.

10 29. A method of amplifying a detectable signal used to detect and quantify an antigen in an immunoassay which comprises:

15 (a) directly or indirectly binding to an analyte a biochemical molecular probe comprising a binding domain (A), and a second domain (M) which comprises a multiplicity of single-stranded DNA oligomeric subunits capable of hybridizing to a single-stranded labeled oligonucleotide;

(b) removing unbound probe;

20 (c) hybridizing single-stranded labeled oligonucleotides, which comprise a nucleotide sequence which is substantially complementary to the subunit sequence of the domain M probe, to the subunits of the second domain;

(d) removing unbound labeled oligonucleotide;

25 and

(e) quantifying the amount of labeled oligonucleotide bound to the probe.

30 30. The method of claim 29 in which the analyte is first immobilized, directly or indirectly, on a solid substrate.

31. The method of claim 30 in which domain A is a polypeptide capable of functioning as an antibody, and

35

the probe is bound directly or indirectly to the analyte via domain A.

5 32. The method of claim 31 in which the polypeptide of domain A specifically binds to an epitope of an antibody which specifically binds to the analyte.

33. The method of claim 29 in which:

10 (a) domain A of the probe is a single-stranded polynucleotide; and

(b) the analyte is indirectly bound to the molecular probe via a protein/polynucleotide hybrid linker molecule with two domains:

15 (i) a first domain which is a single-stranded polynucleotide sequence substantially complementary to the sequence of domain A of the probe; and

20 (ii) a second domain which functions as an antibody, specific for the analyte.

34. A method of amplifying a detectable signal in a competitive immunoassay which comprises:

25 (a) constructing a molecular probe comprising:
(i) a first domain (A) which is capable of functioning as an immunogen;

30 (ii) a second domain (B) which is a double-stranded polynucleotide capable of functioning as a promoter for a DNA-dependent RNA polymerase enzyme activity; and

35 (iii) a third domain (C) which is either single- or double-stranded and adjacent to the second domain, such that the third domain is capable of functioning as a

-51-

template for the promoter activity of the second domain;

(b) immobilizing the probe, directly or indirectly, upon a solid substrate in the presence of a competing analyte;

(c) removing unbound probe;

(d) transcribing multiple copies of RNA oligomers which are complementary to the template sequence, c', of the third domain, C, of the probe construct via a DNA-dependent RNA polymerase activity; and

(e) quantifying the RNA transcripts.

35. A method of amplifying a detectable signal in a competitive immunoassay which comprises:

(a) constructing a molecular probe comprising:

(i) a first domain (A) which is capable of functioning as an immunogen; and

(ii) a second domain (M) comprising a multiplicity of single-stranded oligonucleotide subunits that are capable of binding specifically to a single-stranded nucleic acid sequence of interest;

(b) immobilizing the probe, directly or indirectly, upon a solid substrate in the presence of a competing analyte;

(c) removing unbound probe;

(d) hybridizing single-stranded labeled oligonucleotides, which comprise a nucleotide sequence which is substantially complementary to the subunit sequence of the domain M probe, to the subunits of the second domain;

(e) removing unbound labeled oligonucleotide; and

-52-

(f) quantifying the amount of labeled
oligonucleotide bound to the probe.

5

10

15

20

25

30

35

1/11

A -

— A —|— B —|— C —

5'— —|— b —|— c —

antibody-AAAAAAAAA —|— b' —|— c' —

B -


< A > < B (T7PROMOTER) >

5'-TTTTTTTTTCTGGCTTATCGAAATTAATACGACTCACTATA...


ANTIBODY-3'-AAAAAAAAAGACCGAATAGCTTTAATTATGCTGAGTGATAT...

< C (TRANSCRIBED REGION) >
 ...GGGAGATGTGGTTGTCGTA CT TAGCGAAATACTGTCCGAGTCG
 ...CCCTCTACACCAACAGCATGAATCGCTTTATGACAGGCTCAGC
 template strand

C -



D -



2/11




Figure 2

SUBSTITUTE SHEET

3/11





Figure 3

SUBSTITUTE SHEET

5/11

Figure 4b



SUBSTITUTE SHEET

6/11

C. Branched DNA, Fork Structures.





Figure 4c

7/11

D. Multiple Forks (through solution assembly).



- 1) Splicing linker used for T₄ ligase.
- 2) Chemical ligation also possible.




Figure 4d

E. Forked comb structures.





Figure 4e

10/11

D. Multiple Comb Structure



INTERNATIONAL SEARCH REPORT

International Application No. **PCT/US91/02925**

I. CLASSIFICATION OF SUBJECT MATTER (if several classification symbols apply, indicate all) ⁶ According to International Patent Classification (IPC) or to both National Classification and IPC IPC(5): G01N 33/539; C12Q 1/68 U.S. Cl.: 435/7.91,6		
II. FIELDS SEARCHED		
Minimum Documentation Searched ⁷		
Classification System	Classification Symbols	
U.S.	435/6,7.72,7.91,7.92,7.94,91,172.3,805,972; 436/501,518,539,819; 530/387,391,402; 536/27,126; 935/17,78,81,110	
Documentation Searched other than Minimum Documentation to the Extent that such Documents are Included in the Fields Searched ⁸		
III. DOCUMENTS CONSIDERED TO BE RELEVANT ⁹		
Category ⁹	Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages ¹²	Relevant to Claim No. ¹³
Y	WO, A. 90/02819 (CHU ET AL.) 22 March 1990 see especially page 4, line 35. through page 5, line 32.	1-35
Y	Nucleic Acids Research, Volume 14, Number 14, issued 1986, Chu et al., "Synthesis of an amplifiable reporter RNA for bioassays", pages 5591-5603, see especially the abstract.	1-35
Y	Nucleic Acids Research, Volume 14, Number 2, issued 1986, Syvanen et al., "Fast quantitation of nucleic acid hybrids by affinite-based hybrid collection, "page 5037-5048, see especially the Introduction on pages 5037-5038.	1-35
<div style="display: flex; justify-content: space-between;"> <div style="width: 45%;"> <p>¹⁰ Special categories of cited documents:</p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p> </div> <div style="width: 45%;"> <p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step</p> <p>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.</p> <p>"A" document member of the same patent family</p> </div> </div>		
IV. CERTIFICATION		
Date of the Actual Completion of the International Search		Date of Mailing of this International Search Report
22 August 1991		04 SEP 1991
International Searching Authority		Signature of Authorized Officer
ISA/US		Ardin Marschel

III. DOCUMENTS CONSIDERED TO BE RELEVANT (CONTINUED FROM THE SECOND SHEET)

Category *	Citation of Document, with indication, where appropriate, of the relevant passages	Relevant to Claim No
Y	Nucleic Acids Research. Volume 16, Number 23, issued 1988, Syvanen et al., "Quantitation of polymerase chain reaction products by affinity-based hybrid collection," pages 11327-11338, see especially the abstract.	1-35
A	US.A, 4,299,916 (LITMAN ET AL.) 10 November 1981, see especially column 27, line 11. through column 38. line 32.	1-35
A	US.A, 4,563,419 (RANKJ ET AL.) 07 January 1986, see especially claims 1-8.	1-35
A	US, A. 4,910,300 (URDEA ET AL.) 20 March 1990, see especially claims 1-6.	1-35
A	US.A, 4,828,979 (KLEVAN ET AL.) 09 May 1989, see especially column 1, line 13, through column 2, line 27.	18,19,27
A	EP.A.O.225,807 (URDEA ET AL.) 16 June 1987, see especially the abstract.	1-35
Y	US.A. 4,882,269 (SCHNEIDER ET AL.) 21 November 1989, see especially column 14, lines 13-50.	1-35
Y	US.A,4,749,647 (THOMAS ET AL.) 07 June 1988, see especially column 4, line 14, through column 5, line 18.	1-35
Y	WO,A, 87/06270 (CHU ET AL.) 22 October 1987, see especially the abstract and page 2, line 27, through page 4, line 3.	1-35